| Dr Manuel A Cabrera Diaz, MD | |
|
Ave. General Valero Km. 2, Fajardo, PR 00738 | |
| (787) 655-0505 | |
| (787) 655-5021 |
| Full Name | Dr Manuel A Cabrera Diaz |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | Ave. General Valero Km. 2, Fajardo, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649386699 | NPI | - | NPPES |
| 282-89 | Other | PR | TRIPLE S |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 6227 (Puerto Rico) | Primary |
| Entity Name | Anestesia Del Caribe Csp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649237827 PECOS PAC ID: 8123173168 Enrollment ID: O20090827000312 |
News Archive
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.
Loss or impairment of the ability to speak is one of the most feared complications of stroke-one faced by about 20% of stroke patients. Language, as one of the most complex functions of the brain, is not seated in a single brain region but involves connections between many regions.
BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.
Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year-;and the potential for the virus to cause even larger outbreaks- researchers are committed to designing a vaccine to stop it.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Manuel A Cabrera Diaz, MD Po Box 1088, Fajardo, PR 00738-1088 Ph: (787) 863-5286 | Dr Manuel A Cabrera Diaz, MD Ave. General Valero Km. 2, Fajardo, PR 00738 Ph: (787) 655-0505 |
News Archive
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.
Loss or impairment of the ability to speak is one of the most feared complications of stroke-one faced by about 20% of stroke patients. Language, as one of the most complex functions of the brain, is not seated in a single brain region but involves connections between many regions.
BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.
Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year-;and the potential for the virus to cause even larger outbreaks- researchers are committed to designing a vaccine to stop it.
› Verified 5 days ago
Dr. Hiram Efrain Isaac, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 54 Calle Celis Aguilera N, Fajardo, PR 00738 Phone: 939-465-1196 |